Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4675283 | 0.81 | HTR6 (0.76) | HTR6 | |
| SCHEMBL3326633 | 0.80 | HTR6 (1.00) | HTR6 | |
| Hydrochloric Acid SCHEMBL7008069 | 0.76 | HTR6 (0.91) | HTR6 | |
| SCHEMBL6548285 | 0.74 | HTR6 (0.62) | HTR6GHSR | |
| SCHEMBL6549721 | 0.74 | HTR6 (0.62) | HTR6GHSR | |
| SCHEMBL4676473 | 0.71 | HTR6 (0.65) | HTR6 | |
| SCHEMBL4309989 | 0.71 | HTR6 (0.65) | HTR6 | |
| SCHEMBL8960443 | 0.70 | HTR6 (0.56) | HTR6 | |
| SCHEMBL28797138 | 0.70 | HTR6 (0.56) | HTR6 | |
| Hydrochloric Acid SCHEMBL6047565 | 0.70 | HTR6 (0.64) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449486-B2 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. (US) | 2008-11-11 | — | — | US | claimed |
| EP-1542973-B1 | 2,4-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | claimed |
| CN-1301970-C | 2, 4-substituted indoles and their use as 5-HT 6 modulators | HOFFMANN LA ROCHE (CH) | 2007-02-28 | — | — | CN | claimed |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. | 2006-05-11 | — | — | US | claimed |
| CN-1681783-A | 2, 4-substituted indoles and their use as 5-HT 6 modulators | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | claimed |
| EP-1542973-A1 | 2,4-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | claimed |
| WO-2004026831-A1 | 2,4-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | claimed |
| US-20180334441-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-10017482-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170066733-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-9499503-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9102639-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150210658-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-7381739-B2 | Antiserotonine agents; central nervous system disorders; Alzheimer's disease; Parkinson's disease; Huntington's disease; sleep disorders | ROCHE PALO ALTO LLC (US) | 2008-06-03 | — | — | US | disclosed |
| CN-1301970-C | 2, 4-substituted indoles and their use as 5-HT 6 modulators | HOFFMANN LA ROCHE (CH) | 2007-02-28 | — | — | CN | disclosed |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. | 2006-05-11 | — | — | US | disclosed |
| CN-1681783-A | 2, 4-substituted indoles and their use as 5-HT 6 modulators | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | disclosed |
| EP-1542973-A1 | 2,4-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20040072844-A1 | 2,4-Substituted indoles and methods of use | ROCHE PALO ALTO LLC | 2004-04-15 | — | — | US | disclosed |
| WO-2004026831-A1 | 2,4-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210658-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | HTR6 4299/4885GHSR 4390/4885 |
| US-20180334441-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF18B, KIF18A | HTR6 4470/4885GHSR 4494/4885 |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | KIF5B, KIF2C, KIFC1 | HTR6 4707/4885GHSR 4355/4885 |
| US-20040072844-A1 | 2,4-Substituted indoles and methods of use | IDO1, IDO2, CYP4B1 | HTR6 130/4885GHSR 960/4885 |
| US-10017482-B2 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF18B, KIF18A | HTR6 4470/4885GHSR 4494/4885 |
| US-20170066733-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF18B, KIF18A | HTR6 4470/4885GHSR 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.